These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25511775)

  • 1. Letter: safe and effective cessation of long-term nucleos(t)ide analogue therapy in noncirrhotic patients with HBeAg-negative chronic hepatitis B.
    Hadziyannis SJ
    Aliment Pharmacol Ther; 2015 Jan; 41(2):236-7. PubMed ID: 25511775
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs.
    Janssen HL; Lau GK
    Hepatology; 2005 Dec; 42(6):1459; author reply 1459-60. PubMed ID: 16317685
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.
    Patwardhan VR; Sengupta N; Bonder A; Lau D; Afdhal NH
    Aliment Pharmacol Ther; 2014 Oct; 40(7):804-10. PubMed ID: 25109610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
    Dakin H; Fidler C; Harper C
    Value Health; 2010 Dec; 13(8):934-45. PubMed ID: 20825624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis.
    Wei W; Wu Q; Zhou J; Kong Y; You H
    Int J Environ Res Public Health; 2015 Aug; 12(8):10039-55. PubMed ID: 26308024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?
    Papatheodoridis GV
    Liver Int; 2013 Feb; 33 Suppl 1():151-6. PubMed ID: 23286859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice.
    Geng M; Li Y; Gao F; Sun L; Yang X; Wang R; Chen J; Zhang Q; Wan G; Wang X
    Int J Infect Dis; 2017 Sep; 62():18-25. PubMed ID: 28669850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice.
    Lampertico P
    J Hepatol; 2009 Apr; 50(4):644-7. PubMed ID: 19231017
    [No Abstract]   [Full Text] [Related]  

  • 11. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?
    Moreno-Cubero E; Del Arco RTS; Peña-Asensio J; de Villalobos ES; Míquel J; Larrubia JR
    World J Gastroenterol; 2018 May; 24(17):1825-1838. PubMed ID: 29740199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
    Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
    J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B.
    Peng J; Cao J; Yu T; Cai S; Li Z; Zhang X; Sun J
    Saudi J Gastroenterol; 2015; 21(4):245-53. PubMed ID: 26228369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients.
    He D; Guo S; Zhu P; Tao S; Li M; Huang H; Wang J; Wang Y; Ding M
    Clin Microbiol Infect; 2014 Oct; 20(10):O687-93. PubMed ID: 25469947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs.
    Li T; Liu F; Zhang L; Ye Q; Fan X; Xue Y; Wang L
    Saudi J Gastroenterol; 2018; 24(1):30-36. PubMed ID: 29451182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in China.
    Qi X; Wang JY; Mao RC; Zhang JM
    J Viral Hepat; 2015 Jan; 22(1):46-54. PubMed ID: 25402626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of nucleos(t)ide analogues and analysis of the short-term prognosis in patients with HBV-related acute-on-chronic liver failure].
    Xiong T; Hu A; Jiang S; Ying H; Deng Q; Zhou W
    Zhonghua Gan Zang Bing Za Zhi; 2015 Sep; 23(9):707-10. PubMed ID: 26524369
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis B Flare After Cessation of Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B: To Retreat or Not to Retreat.
    Liaw YF
    Hepatology; 2021 Feb; 73(2):843-852. PubMed ID: 32810321
    [No Abstract]   [Full Text] [Related]  

  • 20. Serum NGAL can act as an early renal safety biomarker during long-term nucleos(t)ide analogue antiviral therapy in chronic hepatitis B.
    Carey I; Byrne R; Childs K; Horner M; Bruce M; Wang B; Dusheiko G; Agarwal K
    J Viral Hepat; 2018 Oct; 25(10):1139-1150. PubMed ID: 29660209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.